Here are answers to some of the most frequently asked questions by health professionals.
Do contact us at one or our call centres if you have any questions that are not covered.
If a woman has not bled since taking the medication or has not experienced any cramps or is still experiencing signs of pregnancy such as nausea, tenderness of her breasts, etc. she can be relatively certain she is still pregnant. A pelvic examination by a health care provider or an ultrasound is advisable to determine on-going pregnancy as well as to rule out an ectopic pregnancy.
If the pregnancy is ongoing and not an ectopic pregnancy, a surgical evacuation should be provided. If the abortion is incomplete, the health care provider can determine whether to give additional misoprostol or else perform a surgical evacuation (vacuum aspiration ) of the pregnancy.
There is a slight risk of birth defects in the event of an on-going pregnancy following misoprostol use. This should be explained to the woman and termination suggested as the preferred option. The risk of birth effects is estimated less than 1%.
No data exists to show any adverse long-term effects on a woman’s health due to medical abortion.
There is no age limit for using Mariprist, however local regulations regarding the use of products for minors should be taken into consideration.
Women who are breastfeeding may take mifepristone and misoprostol for MA. There is no evidence to suggest that either medication is harmful to babies. Misoprostol enters breast milk soon after taken, and it is likely that mifepristone does as well. Women who are worried can breastfeed immediately before taking the Mariprist tablets or wait four to five hours after taking all of the tablets.
Store between 50°F (10°C) – 77°F (25°C), and protect from moisture and humid conditions where possible.